Auryxia

Common Brands Auryxia ​
Drug Class
Phosphate binder
Controlled Substance Classification
Not a controlled medication
Generic Status
No Lower-cost generic available
Availability
Prescription only
Allison Barnes, PharmD
Allison Barnes, PharmD
Read More
Medically reviewed by Allison Barnes, PharmD last update on 20/12/2023

Overview

Auryxia is an iron-based, orally administered treatment drug. It is mainly prescribed to control or treat certain disorders associated with kidney disease, such as hyperphosphatemia and iron deficiency anemia in patients with CKD not requiring dialysis. 

Its distribution brand is Akebia Therapeutics, with the active ingredient ferric citrate, being a compound of both iron and citrate. Auryxia is not only a phosphate binder but also an iron source that addresses two complications created by this patient with CKD.

Phosphate binder control is important because CKD patients are usually plagued by excessive phosphate levels in the blood, which they cannot get rid of since the nephrons are not functioning efficiently in filtering out excess phosphate.

DRUG STATUS

Availability

Prescription only

Pregnancy & Lactation

Pregnancy